Pandemic (H1N1) 2009 and seasonal influenza A (H1N1) co-infection, New Zealand, 2009

Matthew Peacey; Richard J Hall; Stephanie Sonnberg; Mariette Ducatez; Shevaun Paine; Mackenzie Nicol; Jacqui C Ralston; Don Bandaranayake; Virginia Hope; Richard J Webby; Sue Huang

doi:10.3201/eid1610.100116

Pandemic (H1N1) 2009 and seasonal influenza A (H1N1) co-infection, New Zealand, 2009

Emerg Infect Dis. 2010 Oct;16(10):1618-20. doi: 10.3201/eid1610.100116.

Authors

Matthew Peacey¹, Richard J Hall, Stephanie Sonnberg, Mariette Ducatez, Shevaun Paine, Mackenzie Nicol, Jacqui C Ralston, Don Bandaranayake, Virginia Hope, Richard J Webby, Sue Huang

Affiliation

¹ The Institute of Environmental Science and Research, National Centre for Biosecurity and Infectious Disease, Upper Hutt, New Zealand. mathew.peacey@esr.cri.nz

Abstract

Co-infection with seasonal influenza A (H1N1) and pandemic (H1N1) 2009 could result in reassortant viruses that may acquire new characteristics of transmission, virulence, and oseltamivir susceptibility. Results from oseltamivir-sensitivity testing on viral culture suggested the possibility of co-infections with oseltamivir-resistant (seasonal A [H1N1]) and -susceptible (pandemic [H1N1] 2009) viruses.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antiviral Agents / pharmacology
Child
Disease Outbreaks*
Drug Resistance, Viral
Female
Humans
Influenza A Virus, H1N1 Subtype / classification*
Influenza A Virus, H1N1 Subtype / drug effects
Influenza A Virus, H1N1 Subtype / genetics
Influenza A Virus, H1N1 Subtype / isolation & purification
Influenza, Human* / epidemiology
Influenza, Human* / virology
Male
Microbial Sensitivity Tests / methods
Middle Aged
New Zealand / epidemiology
Oseltamivir / pharmacology
Pandemics*
Seasons*
Virus Cultivation
Young Adult

Substances

Antiviral Agents
Oseltamivir